Yasmin Hurd

As a child growing up in Jamaica, Hurd was particularly interested in how the brain works. To aid in covering her expenses for college, she decided to work in a research lab, which required her to take care of animals. This experience was one that sparked her childhood curiosity and set her on a path to a career in neuroscience research. She completed her PhD at the Karolinska Institutet in Stockholm, Sweden, where her work with micro-dialysis led to advances in neuropharmacology. She spent time as a Pharmacology Research Associate Fellow with the National Institutes of Health and Staff Fellow at the National Institute of Mental Health. == Career ==

Hurd's career began when she returned to her alma mater, Karolinska Institute as a faculty member and professor for 13 years before beginning her career at Mount Sinai. At Mount Sinai, Hurd is currently the Ward-Coleman Chair of Translational Neuroscience and the Director of the Addiction Institute of Mount Sinai within the Behavioral Health System. She is also the former director of the medical school's combined MD/PhD Medical Scientist Training Program. Hurd served on advisory boards including the Clinical Neuroendocrinology Branch, National Institute of Mental Health (NIMH), National Institute of Drug Abuse (NIDA) Board of Scientific Counselors and the Center for Scientific Review (CSR) advisory Council. Hurd is a professor at the Icahn School of Medicine at Mount Sinai Hospital in New York City, where she studies addiction in people and animal models. Her animal research has revealed that drugs like marijuana can have profound effects on the developing and fetal adolescent brain, including effects that can even extend to the future generations of drug-users. Her work on the neurobiology of addiction, especially with regard to the effects of heroin and the developmental changes caused by cannabis, have been profiled in a variety of popular news and documentary sources. == Research ==

Hurd’s research focuses on the effects of cannabis and heroin on the brain. Her pre-clinical research is complemented with clinical laboratory investigations evaluating the therapeutic potential of medications such as the use of phytocannabinoids in the treatment of psychiatric disorders. Grants Ongoing research grants as of 2020: ==Publications==

Partial list ranked by third-party citations: • Cited by 511 publications. • Cited by 449 publications. • Cited by 393 publications. Cited by 246 publications. Cited by 390 publications. Cited by 357 publications. Cited by 309 publications. == Professional affiliations ==

A partial list of professional affiliations and committees includes: Elected Member, National Academy of Medicine; American Society for Neuroscience; New York Academy of Sciences; The College on Problems of Drug Dependence; Vice-Chair, ACNP Minority Task Force; Editorial Board Member, Biological Psychiatry; Brain & Behavior Research Foundation, Scientific Council member; Editorial Board Member, Cannabis and Cannabinoid Research; Editorial Board, National Academies’ Forum on Neuroscience and Nervous System Disorders, and member, the SfN Public Education and Communication Committee. Professional societies include: American College Neuropsychopharmacology, Society for Neuroscience, New York Academy of Sciences, College on Problems of Drug Dependence, and the Society for Biological Psychiatry. ==References==